Impact Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor
Status:
Completed
Trial end date:
2020-12-21
Target enrollment:
Participant gender:
Summary
Postoperative delirium is one of the most common serious complications after major surgery
and is associated with undesirable consequences. Prevention of postoperative delirium is
recommended in the clinical guidelines and consensus statements. Dexmedetomidine, a highly
selective α2-adrenergic receptor agonist, has been investigated as a pharmacological
intervention to prevent postoperative delirium. Several randomized controlled trials have
shown that prophylactic use of low-dose dexmedetomidine may decrease the incidence of
postoperative delirium in patients after cardiac and non-cardiac operations. However,
neurosurgical patients are often excluded from previous studies due to potential
consciousness and cognition impairment. The investigators design this pilot study aiming to
clarify the feasibility and safety of use of low-dose dexmedetomidine for prevention of
postoperative delirium in patients after intracranial operation for brain tumor.